VOLGA trial : The Arm1 - in MIBC, neoadjuvant Durvalumab + EV followed by surgery then adjuvant Durvalumab showed better EFS (NR vs 12 months HR 0.51) and OS (NR in both arms, HR 0

Abeid Athman (Omar).· @bin_abeid · X·2026-10-24 23:32· 23 hours agoScore70

Body

VOLGA trial : The Arm1 - in MIBC, neoadjuvant Durvalumab + EV followed by surgery then adjuvant Durvalumab showed better EFS (NR vs 12 months HR 0.51) and OS (NR in both arms, HR 0.58) compared to the standard of care. #ESMO2026 @DrChoueiri @myESMO @darioT_ @E_de_Azambuja

38 views · 1 like · 0 reposts · 0 replies

Conference abstracts

LBA2matched by Presidential Symposium I

Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial

https://esmocongress.esmo.org

NCT04960709NCT04960709matched by VOLGA

VOLGA

https://esmocongress.esmo.org

Source: Abeid Athman (Omar). · x.com